Breast Cancer Clinical Trials in Tucson, AZ

37 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy	Phase 2	BioNTech SE	3 mi
CARE: Cancer Risk Perception and Women of Color	—	Mayo Clinic	3 mi
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)	Phase 3	AstraZeneca	3 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Phase 3	National Cancer Institute (NCI)	3 mi
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study	Phase 2	GlaxoSmithKline	3 mi
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)	Phase 3	DualityBio Inc.	3 mi
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	—	Agendia	3 mi
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.	Phase 3	BriaCell Therapeutics Corporation	3 mi
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer	Phase 2	Atossa Therapeutics, Inc.	3 mi
ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies	Phase 1/2	ALX Oncology Inc.	3 mi
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer	Phase 3	Jazz Pharmaceuticals	3 mi
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss	N/A	Cooler Heads Care Inc.	3 mi
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	Phase 2	QuantumLeap Healthcare Collaborative	3 mi
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects	Phase 3	Greenwich LifeSciences, Inc.	3 mi
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors	Phase 2	Seagen, a wholly owned subsidiary of Pfizer	3 mi
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer	Phase 3	NRG Oncology	3 mi
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial	Phase 2	National Cancer Institute (NCI)	3 mi
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project	Phase 2	University of Arizona	3 mi
CtDNA Based MRD Testing for NAC Monitoring in TNBC	—	Personalis Inc.	3 mi
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence	Phase 3	Stemline Therapeutics, Inc.	3 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer	Phase 3	Canadian Cancer Trials Group	3 mi
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	Phase 1	Relay Therapeutics, Inc.	3 mi
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)	Phase 3	AstraZeneca	3 mi
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer	Phase 2	Processa Pharmaceuticals	3 mi
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)	Phase 3	Eli Lilly and Company	3 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer	N/A	SWOG Cancer Research Network	3 mi
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)	Phase 2	Criterium, Inc.	3 mi
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer	Phase 3	Olema Pharmaceuticals, Inc.	3 mi
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation	Phase 3	AstraZeneca	3 mi
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)	N/A	University of Arizona	3 mi
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 3	Sermonix Pharmaceuticals Inc.	3 mi
Adaptive Symptom Self-Management Immunotherapy Study	N/A	University of Arizona	3 mi
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types	Phase 1/2	Eisai Inc.	3 mi
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain	Phase 3	NRG Oncology	3 mi
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)	Phase 1/2	Genmab	3 mi
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Phase 1	Clasp Therapeutics, Inc.	3 mi
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	Phase 1	Tizona Therapeutics, Inc	3 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.